<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30249872</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>11</Month>            <Day>02</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>02</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1998-4138</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>14</Volume>                    <Issue>Supplement</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Journal of cancer research and therapeutics</Title>                <ISOAbbreviation>J Cancer Res Ther</ISOAbbreviation>            </Journal>            <ArticleTitle>The clinical importance of serum galectin-3 levels in breast cancer patients with and without metastasis.</ArticleTitle>            <Pagination>                <MedlinePgn>S583-S586</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.4103/0973-1482.176425</ELocationID>            <Abstract>                <AbstractText Label="Objective" NlmCategory="UNASSIGNED">Studies have investigated expression status of galectin-3 (Gal-3), but very little is known about the importance of circulating Gal-3 in patients with breast cancer (BC). The purpose of the study was to investigate the clinical significance and potential diagnostic value of plasma Gal-3 levels in patients with BC.</AbstractText>                <AbstractText Label="Materials and Methods" NlmCategory="UNASSIGNED">Fifty-two patients with BC and 35 age-matched healthy controls were enrolled. Levels of Gal-3 were investigated in BC patients and healthy controls. Gal-3 levels were determined using ELISA method.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Serum Gal-3 levels were significantly higher in BC patients than in controls (P = 0.002). Gal-3 levels did not significantly differ according to patients' statuses of lymph node involvement, hormone receptor, lymphovascular invasion, e-cadherin, menopausal, stage, serum hemostatic markers (prothrombin time, partial thromboplastin time, and international normalized ratio), platelet counts, mean platelet volume, lactate dehydrogenase, carcinoembryonic antigen, and carbohydrate antigen 15-3 values (P &gt; 0.05 for all). A cut-off value of Gal-3 to predict BC was determined at â‰¥3.17 ng/ml with a sensitivity of 75.0%, a specificity of 65.71%, a positive and negative predictive values of 76.5 and 63.9%, respectively (area under the curve: 0.705 [95% confidence interval, 0.598-0.798], P = 0.0002).</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Serum Gal-3 levels were significantly higher in BC patients and did not significantly differ according to clinical and tumoral characteristics of patients. Furthermore, there was no difference in Gal-3 levels between BC patients with and without metastatic disease. Serum Gal-3 levels can be used as an adjunct to other diagnostic or screening tests for BC regardless of clinical and tumoral characteristics of patients.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Topcu</LastName>                    <ForeName>Turkan Ozturk</ForeName>                    <Initials>TO</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kavgaci</LastName>                    <ForeName>Halil</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gunaldi</LastName>                    <ForeName>Meral</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kocoglu</LastName>                    <ForeName>Hakan</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Akyol</LastName>                    <ForeName>Murat</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Manisa Public Hospital, Manisa, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mentese</LastName>                    <ForeName>Ahmet</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biochemistry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yaman</LastName>                    <ForeName>Serap Ozer</ForeName>                    <Initials>SO</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biochemistry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Orem</LastName>                    <ForeName>Asim</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biochemistry, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ozdemir</LastName>                    <ForeName>Feyyaz</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Aydin</LastName>                    <ForeName>Fazil</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, School of Medicine, Karadeniz Technical University, Trabzon, Turkey.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>India</Country>            <MedlineTA>J Cancer Res Ther</MedlineTA>            <NlmUniqueID>101249598</NlmUniqueID>            <ISSNLinking>1998-4138</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C000621856">CA153 protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D002272">Carcinoembryonic Antigen</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D037502">Galectin 3</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000951" MajorTopicYN="N">Antigens, Neoplasm</DescriptorName>                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002272" MajorTopicYN="N">Carcinoembryonic Antigen</DescriptorName>                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D037502" MajorTopicYN="N">Galectin 3</DescriptorName>                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010314" MajorTopicYN="N">Partial Thromboplastin Time</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011517" MajorTopicYN="N">Prothrombin Time</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">cut-off value</Keyword>            <Keyword MajorTopicYN="N">galectin-3</Keyword>            <Keyword MajorTopicYN="N">metastasis</Keyword>        </KeywordList>        <CoiStatement>There are no conflicts of interest</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>27</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30249872</ArticleId>            <ArticleId IdType="pii">JCanResTher_2018_14_10_583_176425</ArticleId>            <ArticleId IdType="doi">10.4103/0973-1482.176425</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>